CD24FC
As of the edition of 20 October 2026, CD24FC is a drug: stopped in 2023; acts on HMGB1, HSP90AA1 and HSP90AB1 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Unknown
- Registered trials
- 7, 4 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Infections; Lungs and airways; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product5 company-target rows are on route A because of CD24FC.
See the 5 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 1 | 0 | 3 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2014 to now |